Lauren Colbert

Professor

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Lauren Colbert is an Assistant Professor at the University of Texas MD Anderson Cancer Center in the United States. Her research focuses on cancer treatment modalities and the interplay between the microbiome and various cancers, particularly cervical and ovarian cancers. Recent publications highlight her work on biomarkers for treatment response and the immune characteristics of tumors. She is actively engaged in studies involving HPV-related cancers and the effects of chemoradiation therapy.

Articles (24)

Purpose: Primary urethral adenocarcinoma (PAC) is a rare malignancy associated with poor outcomes. There are 2 primary subtypes—clear cell adenocarcinoma (CCAC) and non–clear cell adenocarcinoma (nCCAC). In this study, we compare oncologic outcomes between CCAC vs nCCAC histological subtypes and describe differences in treatment modalities. Materials and Methods: We performed a retrospective review of patients diagnosed with PAC at our institution between 1993 to 2024. Survival analysis was stratified by histologic subtype (CCAC vs nCCAC) and primary treatment modality. Survival outcomes were stratified by patient age, neoadjuvant therapy (NAT), primary treatment modality, clinical stage, and histological subtype. Results: Of the 35 patients identified, the majority were female, were Black, and presented with locally advanced disease. Most of the patients were treated with radiotherapy (XRT) or surgical extirpation. There were no significant differences in clinical staging or histologic subtype between the 2 treatment modalities. Ten patients were treated with XRT, and 21 patients underwent primary surgical extirpation. Most of the patients received NAT. Locally advanced disease on final pathology was common for both histological subtypes. No patients were downstaged after surgical extirpation, despite nearly all receiving NAT. Survival was significantly better for CCAC vs nCCAC. There was no statistical difference in survival when comparing by treatment modality. Conclusions: PAC represents a rare, aggressive form of cancer. Favorable outcomes among the CCAC cohort may reflect a more favorable disease biology. Despite most of the patients receiving NAT, there were no patients with pathologic downstaging suggesting current neoadjuvant regimens are suboptimal and novel systemic strategies are needed for tumor downstaging to facilitate optimal local tumor control and improved oncologic outcomes.

Year:

2025

PURPOSE Cervical cancer remains a significant public health concern globally and particularly in sub-Saharan Africa, where high rates of HIV infection exacerbate cervical cancer incidence. Understanding the cervical microbiome and its role in cancer progression is essential, especially in regions where both cervical cancer incidence and HIV prevalence are high. This study aimed to characterize the cervical microbiome in women living with HIV (WLWH) and HIV-negative women with squamous cell carcinoma of the cervix in Botswana, compare the microbiome between before and after chemoradiation therapy (CRT) in WLWH, and assess the prognostic value of specific microbial taxa for overall survival (OS) in WLWH. PATIENTS AND METHODS Cervical samples were collected from women with cervical cancer presenting to one hospital in 2018-2019. Patients' clinical data, including HIV status, were recorded. Microbial composition was analyzed using 16S rRNA gene sequencing. Microbiome diversity and composition were evaluated using alpha and beta diversity metrics. Differential microbial abundance was analyzed using linear discriminant analysis effect size. The association between microbial taxa and OS was explored using Cox proportional hazards regression. RESULTS WLWH (n = 42) had a significantly lower Pielou evenness index than HIV-negative women (n = 11; 0.6 v 0.7, P = .02), suggesting a more imbalanced microbiome in WLWH. WLWH had higher levels of Parvimonas and members of the Corynebacteriaceae and Micrococcaceae families, suggesting a shift toward a more pathogenic microbiome. In WLWH, CRT did not significantly alter overall microbial diversity. However, Lactobacillus and Sutterella were enriched before treatment, reflecting a less pathogenic microbiome, whereas Ruminococcus and Phascolarctobacterium and the families Caulobacterales and Flavobacteriia were enriched after treatment, reflecting microbial adaptations to the altered immune and treatment environment. Notably, higher levels of Flavobacteriia after CRT were independently associated with worse OS in WLWH. CONCLUSION Microbiome profiles differ between WLWH and HIV-negative women with cervical cancer in Botswana. The microbiome might have prognostic significance. Future research is needed to better understand the significance of the microbiota in cervical cancer progression and treatment outcomes and the potential role of microbiome-targeted interventions.

Year:

2025

Purpose: Human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design: A total of 66 patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma was collected at baseline, weeks 1, 3, and 5 of chemoRT, and 3 to 4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy. Results: The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared with those who received standard-of-care therapy. HPV cfDNA clearance correlated with better 2-year RFS (92.9% vs. 30%, log-rank; P = 0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index score of 0.83, which improved when combined with MRI response (concordance index, 0.88). Conclusions: HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at follow-up predict RFS, and delivery of therapeutic HPV vaccine with chemoRT was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.

Year:

2025

Year:

2024

Purpose The human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design Sixty-six patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care (SOC) treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma samples were collected at baseline, during weeks 1, 3, and 5 of chemoRT, and 3-4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy. Results The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared to SOC. HPV cfDNA clearance correlated with better 2-yr RFS (92.9% vs. 30%, log-rank p=0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index (CI) 0.83, which improved when combined with MRI response (CI 0.88). Conclusions HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at first follow-up predict RFS, and the therapeutic HPV vaccine was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Aradhana Venkatesan

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Swanson

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lilie L. Lin

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Megan Jacobsen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kyoko Yoshida-Court

Senior Research Scientist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maura L. Gillison

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthew Ning

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Bogdan Czerniak

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Erle S. Robertson

PI

University of Pennsylvania

UNITED STATES
View details

Peng Wei

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details